Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-281: capivasertib + abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer
NL-OMON59128Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate adenocarcinoma and prostate cancer (PCa) comparing Capivasertib + abiraterone with Placebo + abiraterone (2 arms). Primary endpoint: Radiographic progression-free survival. Started Nov 2020; status: active, not recruiting.
02
Drugs
capivasertib
03
Conditions
prostate adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59128.